Lipid Nanoparticle-based mRNA Therapeutics for Infectious Diseases

Area of Science:

• Biotechnology
• Vaccinology
• Infectious Disease Therapeutics

Background:

• Infectious diseases pose significant global health challenges, with existing treatments facing limitations in efficacy and adaptability.
• The COVID-19 pandemic accelerated the development and deployment of mRNA vaccines delivered via lipid nanoparticles (LNP-mRNA), showcasing their safety, efficacy, and scalability.

Purpose of the Study:

• To provide a comprehensive overview of recent advancements in LNP-mRNA therapeutics for infectious diseases.
• To discuss strategies for enhancing mRNA stability, intracellular delivery, and targeted release.
• To examine challenges and opportunities in the clinical translation of LNP-mRNA technology.

Main Methods:

• Review of recent preclinical and clinical findings on LNP-mRNA therapeutics.
• Analysis of strategies for improving mRNA stability and LNP formulation.
• Examination of cell-specific and tissue-specific targeting approaches.

Main Results:

• Significant progress has been made in LNP-mRNA platforms targeting Herpes Simplex Virus (HSV), Respiratory Syncytial Virus (RSV), Zika virus, Rabies virus, and SARS-CoV-2.
• Advances in lipid nanoparticle formulation and mRNA sequence engineering are enabling enhanced therapeutic potential.
• Key strategies focus on improving mRNA stability, intracellular delivery, and controlled release.

Conclusions:

• LNP-mRNA therapeutics hold transformative potential for developing next-generation, personalized treatments against a wide range of infectious diseases.
• Overcoming translational challenges in LNP composition, biocompatibility, and immune interactions is crucial for clinical success.
• The success of LNP-mRNA technology offers a promising avenue for future infectious disease control.